论文部分内容阅读
肺动脉高压(PAH)是肺血管和肺实质发生病变的主要表现,当肺动脉压超过30/15mmHg或其平均压超过20mmHg时,即形成PAH。采用血管扩张药治疗PAH,因减小肺动脉压和肺血管阻力,减轻呼吸困难,增加心输出量,并提高病人运动耐受性,近年引起人们普遍重视。本文结合血管扩张药治疗PAH的血液动力学效应,对目前血管扩张药治疗PAH的临床应用情况,作一简要介绍。
Pulmonary hypertension (PAH) is a major manifestation of lesions in the pulmonary blood vessels and pulmonary parenchyma, which form PAH when pulmonary arterial pressure exceeds 30/15 mmHg or its mean pressure exceeds 20 mmHg. The use of vasodilators in the treatment of PAH, due to reduced pulmonary artery pressure and pulmonary vascular resistance, reduce dyspnea, increase cardiac output, and improve patient tolerance to exercise, in recent years caused widespread attention. This article combines the vasodilators in the treatment of PAH hemodynamic effects of the current vasodilator treatment of PAH clinical application, make a brief introduction.